GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tectonic Therapeutic Inc (NAS:TECX) » Definitions » Forward PE Ratio

TECX (Tectonic Therapeutic) Forward PE Ratio : 0.00 (As of Apr. 28, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Tectonic Therapeutic Forward PE Ratio?

Tectonic Therapeutic's Forward PE Ratio for today is 0.00.

Tectonic Therapeutic's PE Ratio without NRI for today is 0.00.

Tectonic Therapeutic's PE Ratio (TTM) for today is 0.00.


Tectonic Therapeutic Forward PE Ratio Historical Data

The historical data trend for Tectonic Therapeutic's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tectonic Therapeutic Forward PE Ratio Chart

Tectonic Therapeutic Annual Data
Trend
Forward PE Ratio

Tectonic Therapeutic Quarterly Data
Forward PE Ratio

Competitive Comparison of Tectonic Therapeutic's Forward PE Ratio

For the Biotechnology subindustry, Tectonic Therapeutic's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tectonic Therapeutic's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tectonic Therapeutic's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Tectonic Therapeutic's Forward PE Ratio falls into.


;
;

Tectonic Therapeutic Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Tectonic Therapeutic  (NAS:TECX) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Tectonic Therapeutic Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Tectonic Therapeutic's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Tectonic Therapeutic Business Description

Traded in Other Exchanges
N/A
Address
490 Arsenal Way, Suite 210, Watertown, MA, USA, 02472
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.